SCHEMBL23340951

SCHEMBL23340951

Cc1c[nH]c(-c2cccc(Cl)n2)n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.38
CCR1 P32246 1/20 0.38
CCR8 P51685 1/20 0.38
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34
IDH1 O75874 10/20 0.34
IDH2 P48735 8/20 0.34
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
GSK3B P49841 1/20 0.33
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
METAP2 P50579 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6815366 0.87 CCR1 (0.44) CCR1CCR8ALDH1A1MEN1KMT2A
SCHEMBL28856145 0.83 CCR1 (0.58) CCR1CCR8ALDH1A1CYP3A4METAP2
SCHEMBL22051478 0.80 CCR1 (0.39) CCR1CCR8METAP2
SCHEMBL20390730 0.79 NOS3 (0.48) CCR1CCR8IDH1MEN1KMT2A
SCHEMBL3327100 0.73 KDM4E (0.49) CCR1CCR8CYP1A2KMT2AMETAP2
SCHEMBL14722908 0.72 CCR1 (0.73) CCR1CCR8IDH1IDH2CYP3A4
SCHEMBL30077166 0.71 KMT2A (0.42) JAK2CCR1CCR8HTR3EHTR3B
SCHEMBL15347711 0.71 KMT2A (0.42) JAK2CCR1CCR8HTR3EHTR3B
SCHEMBL7507586 0.71 MEN1 (0.32) ALDH1A1MEN1KMT2A
SCHEMBL30492599 0.71 CYP3A4 (0.50) JAK2CCR1CCR8HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10995091-B2 CXCR4 receptor antagonists PROXIMAGEN LLC (US) 2021-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10995091-B2 CXCR4 receptor antagonists CXCR4, CXCR1, CXCR2 JAK2 617/4885CCR1 16/4885CCR8 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.